At Munich’s real estate exhibition last week, Russia’s leading e-commerce company, Ulmart, hosted a “working breakfast” to discuss the nuances and intricacies of investing in Russia today during times of heightened international tension.
The topic, “Making the Case for Star Investment Projects in Russia”, featured Ulmart’s chairman and majority shareholder Dmitry Kostygin; Andrew Kaye, Managing Director and Co-Head of Technology Banking, William Blair International; Calin Anton Business Development Director Russia & CIS, Astron; and, Tim Millard, Regional Director, Head of Consulting Services at Jones Lang LaSalle, Russia.
A lively discussion kicked off about how some in the investment community tend to focus—even obsess—on macro realties at a state-to-state level ignoring many truly interesting project; precisely the types of projects that keep most of the world’s economies developing positively from cycle to cycle.
To view the multimedia release go to:
http://www.multivu.com/players/English/7660751-ulmart-russian-investment-update/
February is American Heart Month, and consumers should be aware that a high-sodium diet can increase their risk of developing high blood pressure. An estimated one in three Americans suffer from high blood pressure, which can increase the risk of developing cardiovascular disease – the leading cause of death in men and women in the United States.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65492-u-s-fda-reduce-sodium-intake-by-using-the-nutrition-facts-label
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
http://www.dualfit.com - This 5 step plyometric cardio circuit is great for burning a serious amount of calories and developing explosive muscles!
Check out Steve's site for more workouts like this:
- http://www.pfitpfun.com
- http://www.dobcx.com
Training Style:
Pyometrics, also known as jump training or plyos
Tools:
Dumbbells or Barbell, pull up bar or pull down cable/band, and box or bench
Training Tips:
Plyometric training, primarily used for athletes not only improves strength, power and stamina, it burns a serious amount of calories too. Watch the training video to reference ideal pace and intensity so you get the most out of this workout. In this circuit, each plyometric movement is followed by a strength movement to help improve both conditioning and muscle tone all in one workout. Plyometric exercises should be explosive and powerful. Rest should be limited.
Stella Artois, part of the Anheuser-Busch family of brands, and Water.org today announced a call to action for all beer lovers who plan to watch this year’s Super Bowl, the most highly watched event of the year. By stocking up on Stella Artois beer for the big game and beyond, people across the country can help provide access to clean water for those in the developing world. More than 663 million people are impacted by the global water crisis today.
From January 15 until April 15 of this year, every purchase of a Stella Artois 12-pack (both bottles and cans, including Stella Artois Cidre) will help Water.org provide 12 months of clean water for one person in the developing world. For those watching the big game at a bar, the purchase of one pint or bottle of Stella Artois will help provide one month of clean water. And as in years past, in 2018 every purchase of a Limited-Edition Stella Artois Chalice will help provide five years of clean water for one person in the developing world.
To view the multimedia release go to:
https://www.multivu.com/players/English/8254751-stella-artois-water-org-super-bowl-party/
Global demand for food has never been higher, as populations skyrocket and developing areas of the world strive to feed their citizens. But in the United States, more than one–third of the food produced is never eaten and a new online survey of U.S. grocery shoppers’ attitudes conducted by Harris Poll on behalf of Sealed Air Corporation (NYSE: SEE) shows that food waste in the U.S. is near the top of the list of consumers’ environmental concerns and they are willing to change behaviors if better informed on the issue. The April 2014 study interviewed over 1,000 U.S. adults (aged 18+) who do at least 25% of their household’s grocery shopping (“American grocery shoppers”).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7270651-sealed-air-2014-food-waste-survey/
With 830 women dying every day from preventable causes related to pregnancy and childbirth, and over 16,000 children under age five dying daily, Bayer and the White Ribbon Alliance today released critical policy recommendations and launched community programs to support the reduction and prevention of maternal, newborn and child mortality in two developing countries.1,2
Established through a three-year $1.3 million commitment from Bayer, these programs will expand work conducted by White Ribbon Alliance in Bangladesh and Zimbabwe to support the United Nations Secretary General’s Every Woman Every Child movement.
This announcement comes at the one-year anniversary of the Bayer/White Ribbon Alliance commitment in support of the Every Woman Every Child movement and will contribute to the success of the Sustainable Development Goals.
To view the multimedia release go to:
http://www.multivu.com/players/English/77126510-bayer-white-ribbon-alliance-self-care/
The Investor Desk Presents US Highland, Inc. (OTC PINK: UHLN), a diversified product development, sales, and marketing company.
Since its founding in 1997 as Highland AB in Sweden, the Texas-based company has been developing and manufacturing high-performance single cylinder and V-twin powertrains used for a variety of applications. In September 2015, the publicly traded company began diversifying its operations, guiding startups in the marketing, reselling, and distributing of their products, as well as helping customers establish their brand and penetrate the U.S. market.
Overseeing the company’s growth is chief executive officer and president Josh Whitaker, a marketing executive with global experience in technology marketing, strategy, and implementation. Whitaker has worked with high-profile brands like Red Bull and Under Armour, as well as industry leading companies like Tucker Rocky Distributing and KTM Motorcycles.
Over the past two decades, US Highland, Inc. has tapped a variety of distribution channels, enabling growing businesses, both domestic and foreign, to launch their products in the United States whether wholesale, retail, or over the Internet.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7660851-us-highland-the-investor-desks-new-company/
Miral and SeaWorld Entertainment, Inc. (NYSE:SEAS) (“SeaWorld”) today announced their partnership to develop SeaWorld Abu Dhabi, a first-of-its-kind marine life themed park on Yas Island. This next generation SeaWorld Abu Dhabi will also include the United Arab Emirates’ (“UAE”) first dedicated marine life research, rescue, rehabilitation and return center with world-class facilities and resources for the care and conservation of local marine life. SeaWorld Abu Dhabi will be the first new SeaWorld without orcas, and will integrate up-close animal experiences, mega attractions and a world class aquarium, bringing the latest technology in visitor engagement.
The partnership brings together Miral’s expertise in developing Yas Island’s portfolio of destinations with SeaWorld’s 50-plus years of theme park, veterinary medicine, marine science and zoological practice and experience.
To view the multimedia release go to:
http://www.multivu.com/players/uk/8002251-miral-announces-seaworld-yas-island/
As America takes steps to improve our energy security, home-grown fuel sources are more important that ever. One of the fuel sources of the future is algae, small aquatic organisms that convert sunlight into energy and store it in the form of oil. Scientists and engineers at the Energy Department and its national laboratories are researching the best strains of algae and developing the most efficient farming practices. This edition of Energy 101 shows how oil is extracted from algae and refined into sustainable biofuels.
For more information on biofuels visit http://www.eere.energy.gov.
Syneron Medical Ltd., the leading global aesthetic device company, announced to a group of international media its new activities and enhanced global commitment to developing the non-invasive body shaping market, one of the fastest growing segments in the global aesthetic medical device market. The press conference took place at the Academy of Medical Sciences in London, just prior to the opening of the BODY Conference and Exhibition, which took place in London on November 3-4, 2012 and for which Syneron was the main sponsor.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58631-body-shaping-by-syneron
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
